Taken together these observations suggest that therapeutic targeting/inhibition of RINF should be considered as a possible therapeutic strategy in human AML, especially for those patients whose leukemia show a higher expression than normal hematopoietic cells. The gene discussed is CXXC5; the disease is acute myeloid leukemia.